Navigation Links
Repligen Reports Second Quarter Fiscal Year 2011 Financial Results
Date:11/2/2010

ssion and alcohol abuse among psychiatric illnesses for related disabilities and overall economic burden of illness.  The lifetime financial burden of bipolar disorder in the United States is about $600,000 per patient, depending on resistance to treatment and persistence of symptoms.  Although several therapies are approved for the treatment of bipolar disorder, many individuals are unable to tolerate the treatment-related side effects, and incomplete clinical response, relapse and recurrence remain common clinical problems.  There are more than five million adults worldwide with bipolar disorder, which is an area of high unmet medical need due to the ineffectiveness and significant side effects of current therapies.

Quarterly Conference CallRepligen will host a conference call and webcast on Tuesday, November 2nd at 3:00 p.m. EDT, to review our financial results, provide a corporate update and discuss financial expectations.  This call can be accessed via Repligen's website at www.repligen.com or by calling (866) 783-2142 for domestic calls and (857) 350-1601 for international calls.  Participants must provide the following passcode: 26826699.

About Repligen CorporationRepligen Corporation is a biopharmaceutical company focused on building an integrated company by developing and marketing innovative drugs that deliver the benefits of protein therapies in the fields of neurology and gastroenterology.  We have a core competency in the development and manufacturing of biologics products, which is the basis for our bioprocessing business and we have out-licensed certain biologics intellectual property, which provide ongoing sources of revenue.  Repligen's corporate headquarters are located at 41 Seyon Street, Building #1, Suite 100, Waltham, MA 02453.  Additional information may be requested at www.repligen.com.REPLIGEN C
'/>"/>

SOURCE Repligen Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Repligen Receives Research Grants to Support Friedreichs Ataxia Development Program
2. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
3. Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT
4. Repligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference Monday, November 10th, 4:55 p.m. EST
5. Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results
6. Repligen to Present at the BIO CEO & Investor Conference Monday, February 9th, 11:30 a.m. EST
7. Repligen Reports Third Quarter Fiscal Year 2009 Financial Results
8. Repligen to Present at the Cowen and Company 29th Annual Healthcare Conference Monday, March 16th, 2:25 p.m. EDT
9. Repligen Announces Conference Call of Fourth Quarter and Fiscal Year 2009 Results
10. Repligen Reports Fourth Quarter and Fiscal Year 2009 Financial Results
11. Repligen Announces Conference Call of First Quarter Fiscal Year 2010 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... CA (PRWEB) November 21, 2014 Why ... that makes Albert Einstein so instantly recognizable? Why have ... physicist, mathematician, astronomer and author Hilton Ratcliffe seeks out ... have nothing at all to do with science. In ... Harbor Publishing , November 21, 2014), Ratcliffe puts it ...
(Date:11/21/2014)... , Nov. 20, 2014 /CNW/ - Aequus ... to announce that it has closed a brokered ... warrants for approximately C$3.7 million.  Cormark Securities Inc. ... in the Brokered Offering for a syndicate of ... PI Financial Corp. (collectively the "Agents"). Concurrently with ...
(Date:11/18/2014)... FL (PRWEB) November 17, 2014 ... point-of-care diagnostic tests – today announces its third ... and Prevention’s (CDC) Get Smart About Antibiotics Week ... Week is a national campaign designed to highlight ... health departments, and non-profit and for-profit partners to ...
(Date:11/18/2014)... 18, 2014 Alanda Software, a ... Reporting solutions, announced today that a top tier ... Consummate Provider™ solution in both the U.S. and ... SaaS based, Data Quality remediation portal, designed to ... party Providers improve their ability to capture, transmit ...
Breaking Biology Technology:“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 2“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 3“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 4Aequus Pharmaceuticals closes $4.2 million private placement financing 2Aequus Pharmaceuticals closes $4.2 million private placement financing 3RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 2RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 3Alanda Software Completes Successful Implementation of Global Data Quality & Vendor Management Solution for Top Tier Global Biopharmaceutical Company 2
... of hazardous waste resulting from the nations nuclear weapons ... state called Hanford. Beneath this desert landscape about ... of tons of chemicals are captured within the stratified ... flow paths. These paths create uncertainties about where ...
... the National Nanotechnology Initiative has just been released by ... of the National Science and Technology Councils Committee on ... (NNCO). The 2007 NNI Strategic Plan describes ... ensure that the United States derives growing economic benefits ...
... Pharmos Corporation,(Nasdaq: PARS ) announced today that ... placement of its 10% Convertible Debentures due November ... principal amount of the,Debentures, at par, and received ... purchasers consisted of certain existing investors in the ...
Cached Biology Technology:Where does stored nuclear waste go? 2National Nanotechnology Initiative releases new strategic plan 2National Nanotechnology Initiative releases new strategic plan 3Pharmos Corporation Completes Initial Closing of Private Placement 2
(Date:11/6/2014)... 2014 - Insilico Medicine, Inc, a Baltimore-based bioinformatics ... related diseases announced a research collaboration with the ... Oncology, Inc (OTC: CSBR). , "There are many ... but Champions Oncology,s TumorGraft technology is unique in ... regimen experimentally generating vast amounts of valuable data. ...
(Date:11/5/2014)... in their ability to identify scents and odors. ... perceptual evaluation of odors, with women outperforming men on ... differences in olfactory detection may play a role in ... perception of smell, which is naturally linked to associated ... suggested to be cognitive or emotional, rather than perceptual. ...
(Date:11/4/2014)... Medicine announced today that it is a Grand ... Bill & Melinda Gates Foundation. Laura Goetzl, ... Sciences; and Vice Chair of Research and Academic ... pursue an innovative global health and development research ... Neurodevelopment.", Grand Challenges Explorations (GCE) funds individuals worldwide ...
Breaking Biology News(10 mins):Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2The female nose always knows: Do women have more olfactory neurons? 2Temple University School of Medicine receives Grand Challenges Explorations grant 2
... RIVERSIDE, Calif. Four researchers at the University of California, ... the Advancement of Science ( AAAS ). Including this year,s ... have been recognized with AAAS Fellow distinction is 194. ... members by their peers. This year AAAS gave this honor ...
... risk of attack has led to the development of ... larval stage. One caterpillar may look like a stick, ... may have its advantages, University of Florida researchers uncovered ... another strategy previously best-known in adult butterflies: mimicry. ...
... , The Ontario Genomics Institute (OGI) has awarded two ... leading-edge technologies to better aid the work of Ontario ... Applied Genomics (TCAG), part of The Hospital for Sick ... and Technology Innovation Centre, and StemCore Laboratories based at ...
Cached Biology News:4 UC Riverside researchers receive national recognition 2Caterpillars mimic one another for survival 2Caterpillars mimic one another for survival 32 research facilities awarded technology seeding grants 2
Mouse monoclonal antibody raised against a full length recombinant YARS. NCBI Entrez Gene ID = YARS...
... DS-L2 imaging controller is a successor of ... allows users to comfortably observe, record and ... features an 8.4 inch LCD (XGA) monitor ... Nikon cameras including the DS-Fi1 , DS-5Mc ...
... NovaTaq DNA Polymerase is a premium ... polymerase. This thermostable enzyme is suitable for ... ensure the highest purity and reproducible performance, ... variety of quality control assays. NovaTaq DNA ...
Mouse polyclonal antibody raised against a partial recombinant TSEN2. NCBI Entrez Gene ID = 80746...
Biology Products: